

KASR ALAINY

Screening of Reduced Susceptibility to Glycopeptides among Staphylococcus aureus isolates

Thesis

Submitted for Fulfilment of the requirement of M.Sc.Degree in Clinical and
Chemical Pathology

Presented by

Noha Salah Eldein Elsayed Ali Soliman

M.B.B.Ch - Faculty of Medicine

Cairo University

Under supervision of

Prof.Dr.Sahar M. Khairat

Professor of Clinical and Chemical Pathology

Faculty of Medicine

Cairo University

Prof.Dr.Mervat G. ElAnany

Assistant Professor of Clinical and Chemical Pathology

Faculty of Medicine

Cairo University

Faculty of Medicine

Cairo University

2011

Acknowledgement

Foremost, all thanks and gratitude to Allah, most gracious and most merciful.

*I would like to express my deepest gratitude and sincere thanks to Prof. **Dr. Amani Ali Elkholy**, Professor of Clinical and Chemical Pathology, Faculty of Medicine, Cairo University For her continuous guidance and valuable advice for enriching this work.*

*I am extremely grateful to Prof.**Dr. Sahar Mohammed Khairat**, Professor of Clinical and Chemical Pathology, Faculty of Medicine, Cairo University for her continuous guidance, saving no effort or time to make this work better.*

*I would like to express my highest appreciation to **Dr. Mervat Gaber Abd El-Wahab**, Assistant professor of Clinical and Chemical Pathology, Faculty of Medicine, Cairo University for her great cooperation, assistance and valuable efforts during the whole work without which, it wouldn't have been a reality.*

*My deepest gratitude to **my family** for their support and encouragement throughout my life.*

Abstract

Staphylococcus aureus is a leading nosocomial pathogen of major worldwide importance. Furthermore, it has been recently implicated in serious community acquired infections. This problem is further confounded by the appearance of S.aureus strains exhibiting reduced susceptibility to vancomycin. Since emergence of methicillin-resistant S.aureus, the glycopeptide (vancomycin) has been the only effective treatment for staphylococcal infections. However, lately S.aureus has developed resistance to glycopeptides and this was associated clinically with treatment failure. This work aimed at studying the prevalence of reduced susceptibility of S.aureus to glycopeptides (vancomycin). In this study, 500 S.aureus isolated from different sample sources were collected over a period of 5 years from hospitalized patients as well as outpatients and staff members. These isolates were subjected to methods of identification and testing methods for the susceptibility to vancomycin in the form of drug agar dilution and E-test. Among the 500 S.aureus isolates, 1.6% showed S.aureus with reduced susceptibility to vancomycin (hVISA) with MIC $\geq 2\mu\text{g/ml}$ of which the majority 87.5% were hospital acquired. Also a tendency to an increase in vancomycin MICs (glycopeptide creep) had been observed over the 5 years. Strict measures of infection control should be applied and increased awareness of the physicians about antibiotics abuse which is essential to combat spread of s.aureus with reduced susceptibility to vancomycin.

Key Words:

Staphylococcus aureus

Vancomycin - glycopeptide

Susceptibility - hVISA

Contents

	Pages
I) Introduction.....	I
II) Aim of the work.....	II
III)Review of literature	
Chapter 1: Staphylococcus aureus.....	1
Chapter 2: Glycopeptides.....	17
Chapter 3: Mechanisms of resistance to glycopeptides.....	21
Chapter 4: Staph.aureus with reduced susceptibility to.....	33
glycopeptides	
Chapter 5: Detection of resistance to glycopeptides among S.aureus	40
Chapter 6: Treatment of S.aureus with reduced susceptibility to VA	55
Chapter 7: Prevention & Infection Control.....	65
IV) Materials & Methods.....	73
V) Results.....	82
VI) Discussion.....	99
VII) Summary.....	109
VIII)References.....	111
IX) Arabic summary	

Abbreviations

BHI	: Brain heart infusion agar
BHIV4or6	: Brain heart infusion with vancomycin concentration 4 or 6µg/ml
CA	: Community acquired
CDC	: Centers of Disease Control and Prevention
CLSI	: Clinical and Laboratory Standard Institute
CUH	: Cairo University hospitals
C.V.L	: Central Venous Line
DM	: Diabetes Mellitus
DNase	: Deoxyribonuclease test
Eap	: Extracellular adherence protein
EARRS	: European Antimicrobial Resistance surveillance
E/M	: Electron Microscope
FnBP	: Fibronectin-binding protein
FTIR	: Fourier transform infra-red spectroscopy
GISA	: Glycopeptide intermediate S.aureus
HA	: Hospital acquired
hGISA	: Heterogeneous glycopeptides intermediate S.aureus
HICPAC	: Hospital Infection Control Advisory Committee
hVISA	: Heterogeneous vancomycin intermediate S.aureus
ICU	: Intensive care unit
IDSA	: Infectious Disease Society of America

LOS	: Length of hospital stay
MAP	: Major histocompatibility complex class II analogous protein
MET	: Macrodilution method E-test
MH	: Mueller-Hinton agar
MHT5	: Mueller-Hinton agar with teicoplanin concentration 5µg/ml
MIC	: Minimal inhibitory concentration
MRSA	: Methicillin-resistant S.aureus
PAP	: Population analysis profile
PBP	: penicillin-binding protein
PCR	: Polymerase chain reaction
PVL	: Panton-Valentine Leucocidin
TEM	: Transmission electron microscopy
TMP-SXT	: Trimethoprim-sulfamethoxazole
TP	: Teicoplanin
TSS	: Toxic shock syndrome
TSST-1	: Toxic shock syndrome toxin-1
V0.5,1,2,4	: Mueller-Hinton agar with different vancomycin concentrations
VA	: Vancomycin
VISA	: Vancomycin-intermediate S.aureus
VRSA	: Vancomycin-resistant S.aureus


List of Tables

	Pages
Table(1):Evaluation of BHIV6, MH-T5 and macro E-test.....	45
Table(2):Antimicrobial therapy for S.aureus infections.....	64
Table(3):Number of isolates collected over 5 years.....	73
Table(4):Sources of isolates included in this study.....	74
Table(5):CLSI interpretative criteria for cefoxitin disc diffusion.....	78
Table(6):Interpretative criteria for for non beta lactam disk diffusion Susceptibility testing.....	79
Table(7):Patient data for the collected isolates.....	82
Table(8):Clinical presentation of S.aureus infected patients.....	84
Table(9):Results of susceptibility to methiciliin among S.aureus isolates.....	85
Table(10):Results of resistance among non-beta lactam antibiotics among HA & CA S.aureus isolates.....	87
Table(11):Results of MIC testing for VA by agar dilution among S.aureus isolates	88
Table(12):Number of HA & CA isolates with MIC $\geq$ 2 μ g/ml by E-test.....	90
Table(13):Results of VA MIC testing by E-test in comparison to agar dilution.....	91
Table(14): Analysis of data for cases that showed MIC for VA $\geq$ 2 μ g/ml by E-test.....	92
Table(15): Comparing results of MIC testing by agar dilution & E-test among the 5 years.....	94

List of figures

	Pages
Fig(1):The virulence determinants of S.aureus.....	7
Fig(2):Surface & secreted proteins in S.aureus.....	7
Fig(3):Sites of infection & diseases caused by S.aureus.....	9
Fig(4):Gram stain of S.aureus in pustular exudates.....	12
Fig(5):Mechanisms of S.aureus resistance to vancomycin:VISA strains.....	22
Fig(6):Model for VA resistance in VISA strains	24
Fig(7):Phenotypic stages of MRSA dependant on presence or absence of selective pressure by vancomycin or beta lactam antibiotics.....	26
Fig(8):Mechanisms of S.aureus resistance to vancomycin: VRSA strains.....	28
Fig(9):Introducton of antibiotics & consequent evolution of resistance in S.aureus	33
Fig(10):Algorithm for testing S.aureus with vancomycin.....	54
Fig(11):Methicillin resistance among CA isolates	86
Fig(12):Methicillin resistance among HA isolates.....	86
Fig(13):MIC agar dilution results for VA among CA isolates.....	89
Fig.(14):MIC agar dilution results for VA among HA isolates.....	89
Fig.(15):MIC agar dilution results for VA among isolates of carriers.....	90
Fig.(16): Incidence of S.aureus with reduced susceptibility to VA among 500 S.aureus isolates.....	93
Fig.(17): Percentage of HA to CA among the 8 isolates with MIC ≥ 2 μ g/ml by E-test.....	94
Fig.(18): Comparing growth results on V0.5 over 5 years.....	95
Fig.(19): Comparing growth results on V1 over 5 years.....	95

Fig.(20): Comparing growth results on V2 over 5 years.....	96
Fig.(21): Comparing MIC results of ≥ 2 $\mu\text{g/ml}$ by E-test over the 5 years.....	96
Fig.(22): E-test showing S.aureus with VA MIC 3 $\mu\text{g/ml}$	97
Fig.(23): E-test showing S.aureus with VA MIC 2 $\mu\text{g/ml}$	98



INTRODUCTION

Introduction

Staphylococcus aureus is one of the most common causes of community acquired and hospital acquired infections.

After initial success of penicillin in treating *staphylococcus aureus* infections, resistance to this drug began to emerge, then methicillin and other semisynthetic methicillins were successful in treating penicillin resistant *staphylococcus aureus* until 1980 when methicillin resistant *staphylococcus aureus* (MRSA) became endemic in hospitals (**Oliveira et al., 2002**).

Since emergence of MRSA, the glycopeptide (vancomycin) has been the only effective treatment for staphylococcal infections.

Lately, *Staphylococcus aureus* has developed resistance to glycopeptides (vancomycin) and the degree of resistance was determined by minimal inhibitory concentration (MIC) testing of the drug (**Hiramatsu et al., 1997**).

Staphylococcus aureus with reduced susceptibility to glycopeptides or vancomycin (VISA or GISA) was first discovered in Japan 1996 and since then, reports of VRSA & VISA among *staphylococcus aureus* isolates have been increasing (**Hiramatsu et al., 1997**).

The clinical significance of emergence of reduced susceptibility to vancomycin among staphylococcus aureus represented in appearance of cases with treatment failure, not responding to the drug.

Aim of the work:

This work aimed at studying the prevalence of reduced susceptibility to glycopeptides represented in vancomycin among staphylococcus aureus isolates collected from hospitalized patients as well as outpatients and staff members in Cairo University Hospitals.

REVIEW OF LITERATURE

CHAPTER (1)

Staphylococcus aureus

Staph aureus has long been recognized as one of the major human pathogens responsible for a wide range of infections. It is a common pathogenic commensal bacterium found in warm moist areas of the body, particularly the nose, axilla, perineum. The basic human habitat of S.aureus is the anterior nares with a nasal carriage of about 20%-50% of the population, but it does not cause harm and does not require treatment. However, some S.aureus carriers constitute a source of infection by disseminating the organism to others (**Haddadin et al., 2002**).

Pathogenesis and Virulence factors:

Staph aureus expresses many potential virulence factors that contribute to its ability for attachment, colonization, cell-cell interaction, immune evasion and tissue damage. The virulence factors can be classified as cell wall associated and extra-cellular component (**Novick et al., 2001**).

A)Cell wall components:(Brooks et al., 2004)

1)Protein A:

It is a cell wall component of many S.aureus strains. It is an important virulence factor because it binds to the Fc portion of IgG, preventing the activation of complement. As a consequence, no C3b is produced, and the opsonization and phagocytosis of the organisms are greatly reduced.

2)Teichoic acids :

They are polymers of ribitol phosphate. They mediate adherence of the Staphylococci to mucosal cells and play a role in the induction of septic